Skip to Navigation

"Sat Dharam has been an amazing guide on many levels. She helped me navigate through a lot of conflicting information about breast cancer and helped me to understand how to go forward with the "right information". As well she has introduced me to a form of yoga that I know will become a part of my daily practice. I can now begin the healing process on an emotional level! Thank you Sat Dharam!" 

— C.R.

Genetic Testing and Chemotherapy Selection

in
  • Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.
  • Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
  • Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
  • Factors predictive of response to hormone therapy in breast cancer.
  • Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
  • Progression and treatment of HER2-positive breast cancer.
  • The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
  • Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial.
  • Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer.
  • Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone.
  • Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
  • Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
  • Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
  • EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
  • p53 as a specific prognostic factor in triple-negative breast cancer
  • Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
  • Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment
  • Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen